Celularity Faces Nasdaq Compliance Issue
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy CELU?
Source: seekingalpha
- Compliance Notice: Celularity received a notice from Nasdaq on April 16, 2026, regarding non-compliance with Listing Rule 5250(c)(1) due to the delayed filing of its Form 10-K for the fiscal year ending December 31, 2025, which could jeopardize its listing status.
- Compliance Plan Deadline: Under Nasdaq rules, the company has 60 calendar days from the notice to submit a compliance plan, and if accepted, it may receive up to 180 days from the original Form 10-K due date to regain compliance.
- Financial Impact: The compliance issue has led to a 0.81% drop in Celularity's shares, which may negatively affect investor confidence and the company's ability to raise funds.
- Strategic Licensing Agreement: Despite facing compliance challenges, Celularity secured a strategic licensing deal worth up to $35 million for its biomaterials portfolio, indicating potential growth opportunities in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CELU?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CELU
About CELU
Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Celularity Faces Nasdaq Compliance Issue
- Compliance Notice: Celularity received a notice from Nasdaq on April 16, 2026, regarding non-compliance with Listing Rule 5250(c)(1) due to the delayed filing of its Form 10-K for the fiscal year ending December 31, 2025, which could jeopardize its listing status.
- Compliance Plan Deadline: Under Nasdaq rules, the company has 60 calendar days from the notice to submit a compliance plan, and if accepted, it may receive up to 180 days from the original Form 10-K due date to regain compliance.
- Financial Impact: The compliance issue has led to a 0.81% drop in Celularity's shares, which may negatively affect investor confidence and the company's ability to raise funds.
- Strategic Licensing Agreement: Despite facing compliance challenges, Celularity secured a strategic licensing deal worth up to $35 million for its biomaterials portfolio, indicating potential growth opportunities in the market.
See More
CELULARITY RECEIVES NASDAQ NOTICE FOR DELAYED FORM 10-K FILING
- Company Announcement: Cellularity has announced the receipt of a notice from NASDAQ regarding a late filing of its Form 10-K.
- Regulatory Compliance: The notice indicates that Cellularity did not meet the deadline for submitting its annual report, which is a requirement for maintaining its listing on NASDAQ.
See More
NEXGEL INC - Agreement Anticipated to Increase Annual Revenue to $35 Million and Achieve Profitability at Closing
- Revenue Expectations: Nexgelin's deal is anticipated to triple its annual revenue to $35 million.
- Profitability Outlook: The company is expected to become profitable upon closing the deal.
See More
NEXGEL INC: $15 Million Upfront Cash and Potential $20 Million in Milestone Payments Included in Consideration
- Financial Details: The deal includes a $15 million upfront cash payment.
- Potential Earnings: There is a possibility of up to $20 million in milestone payments.
See More
NEXGEL Reveals Terms for Licensing and Acquiring a Portfolio of Commercial Regenerative Biomaterial Products
Announcement of Consideration: Nexgel has announced its consideration of terms for an agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products.
Focus on Regenerative Biomaterials: The agreement aims to enhance Nexgel's offerings in the field of regenerative biomaterials, which are used in various medical and commercial applications.
See More
Celularity Enters Strategic Partnership for Biomaterials
- Strategic Partnership: Celularity has entered into definitive agreements for a strategic commercialization partnership that could yield up to $35 million in upfront and milestone payments, significantly enhancing the company's liquidity and market competitiveness.
- Exclusive Licensing: The company granted an exclusive license for its commercial-stage biomaterials portfolio and certain development-stage programs, with the transaction expected to close by April 15, 2026, ensuring future market expansion potential.
- Manufacturing Rights Retained: Celularity will retain exclusive manufacturing rights for the licensed products at its Florham Park, New Jersey facility and will be eligible for royalties on future net sales of certain development-stage products upon commercialization, further strengthening its revenue streams.
- Organizational Realignment: The company plans an organizational realignment, including workforce reductions and the transition of certain personnel to the commercial partner, aimed at lowering operating expenses and improving capital efficiency to better focus resources on advancing its longevity-focused therapeutic pipeline.
See More
Celularity Faces Nasdaq Compliance Issue
- Compliance Notice: Celularity received a notice from Nasdaq on April 16, 2026, regarding non-compliance with Listing Rule 5250(c)(1) due to the delayed filing of its Form 10-K for the fiscal year ending December 31, 2025, which could jeopardize its listing status.
- Compliance Plan Deadline: Under Nasdaq rules, the company has 60 calendar days from the notice to submit a compliance plan, and if accepted, it may receive up to 180 days from the original Form 10-K due date to regain compliance.
- Financial Impact: The compliance issue has led to a 0.81% drop in Celularity's shares, which may negatively affect investor confidence and the company's ability to raise funds.
- Strategic Licensing Agreement: Despite facing compliance challenges, Celularity secured a strategic licensing deal worth up to $35 million for its biomaterials portfolio, indicating potential growth opportunities in the market.
See More
CELULARITY RECEIVES NASDAQ NOTICE FOR DELAYED FORM 10-K FILING
- Company Announcement: Cellularity has announced the receipt of a notice from NASDAQ regarding a late filing of its Form 10-K.
- Regulatory Compliance: The notice indicates that Cellularity did not meet the deadline for submitting its annual report, which is a requirement for maintaining its listing on NASDAQ.
See More
NEXGEL INC - Agreement Anticipated to Increase Annual Revenue to $35 Million and Achieve Profitability at Closing
- Revenue Expectations: Nexgelin's deal is anticipated to triple its annual revenue to $35 million.
- Profitability Outlook: The company is expected to become profitable upon closing the deal.
See More
NEXGEL INC: $15 Million Upfront Cash and Potential $20 Million in Milestone Payments Included in Consideration
- Financial Details: The deal includes a $15 million upfront cash payment.
- Potential Earnings: There is a possibility of up to $20 million in milestone payments.
See More
NEXGEL Reveals Terms for Licensing and Acquiring a Portfolio of Commercial Regenerative Biomaterial Products
Announcement of Consideration: Nexgel has announced its consideration of terms for an agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products.
Focus on Regenerative Biomaterials: The agreement aims to enhance Nexgel's offerings in the field of regenerative biomaterials, which are used in various medical and commercial applications.
See More
Celularity Enters Strategic Partnership for Biomaterials
- Strategic Partnership: Celularity has entered into definitive agreements for a strategic commercialization partnership that could yield up to $35 million in upfront and milestone payments, significantly enhancing the company's liquidity and market competitiveness.
- Exclusive Licensing: The company granted an exclusive license for its commercial-stage biomaterials portfolio and certain development-stage programs, with the transaction expected to close by April 15, 2026, ensuring future market expansion potential.
- Manufacturing Rights Retained: Celularity will retain exclusive manufacturing rights for the licensed products at its Florham Park, New Jersey facility and will be eligible for royalties on future net sales of certain development-stage products upon commercialization, further strengthening its revenue streams.
- Organizational Realignment: The company plans an organizational realignment, including workforce reductions and the transition of certain personnel to the commercial partner, aimed at lowering operating expenses and improving capital efficiency to better focus resources on advancing its longevity-focused therapeutic pipeline.
See More
